1-8 of 8
Nasrin Rastgoo, PhD
Close
Sort by
Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-141495
Published: 2020
Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141409
Published: 2020
Journal Articles

Targeting CD47 and TNFAIP8 By Mir-155 Overcomes Drug Resistance and Inhibits Tumor Growth through Induction of Phagocytosis and Apoptosis in Multiple Myeloma

Nasrin Rastgoo, PhD, Jahangir Abdi, PhD, Maryam Pourabdollah, MD, Hong Chang, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1923.
https://doi.org/10.1182/blood-2018-99-113057
Published: 2018
Journal Articles

Marcks Inhibition By a Peptide Inhibitor, MPS, Cooperates with Bortezomib to Effectively Eliminate Drug Resistance in Multiple Myeloma

Lun Zhang, Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Eldad Zacksenhaus, PhD, Yan Chen, MD PhD, Guoan Chen, MD, Hong Chang, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1936.
https://doi.org/10.1182/blood-2018-99-113026
Published: 2018
Journal Articles

Targeting of Marcks By MiR-34a Overcomes Drug Resistance in Multiple Myeloma

Nasrin Rastgoo, PhD, Yan Chen, MD PhD, Jahangir Abdi, PhD, Minjing Wang, Chen Guoan, MD, Hong Chang, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4377.
https://doi.org/10.1182/blood.V130.Suppl_1.4377.4377
Published: 2017
Journal Articles

Inhibition of the Epigenetic Modifier EZH2 By Mir-138 Upregulates Tumor Suppressor Gene Rbpms and Contributes to Drug Susceptibility in Preclinical Model of Multiple Myeloma

Nasrin Rastgoo, PhD, Maryam Pourabdollah, MD, Jahangir Abdi, PhD BSc, MSc, Hong Chang, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 269.
https://doi.org/10.1182/blood.V130.Suppl_1.269.269
Published: 2017
Journal Articles

Restoration of Mir-138 Expression By Epigenetic Modulation Overcomes Drug Resistance in Multiple Myeloma Cells

Nasrin Rastgoo, PhD, Jahangir Abdi, PhD, Lun Zhang, PhD, Minjing Wang, Hong Chang, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2060.
https://doi.org/10.1182/blood.V128.22.2060.2060
Published: 2016
Journal Articles

Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect

Lun Zhang, PhD, Jahangir Abdi, PhD, Minjing Wang, Nasrin Rastgoo, PhD, Hong Chang, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2061.
https://doi.org/10.1182/blood.V128.22.2061.2061
Published: 2016